Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial
2017-002723-16Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ivermectin in Falciparum malaria (PF) (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Time to microscopically detectable parasitaemia. Started Nov 2017; status: completed.
02
Drugs
ivermectin
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on 2017-002723-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002723-16.